Healthcare Infection Control Practices Advisory Committee (HICPAC), 36240-36241 [E9-17514]
Download as PDF
36240
Federal Register / Vol. 74, No. 139 / Wednesday, July 22, 2009 / Notices
jlentini on DSKJ8SOYB1PROD with NOTICES
Licensing Contact: Peter A. Soukas,
J.D.; 301–435–4646;
soukasp@mail.nih.gov.
A Unique Infectious Hepatitis C Virus
Clone, Strain HC–TN (genotype 1a)
Description of Invention: It is
anticipated that this infectious clone of
hepatitis C virus (HCV) strain HC–TN
(genotype 1a) will be useful for the
development of vaccines and antiviral
drugs that target HCV, genotype 1a. The
HC–TN strain is unique because it has
been shown to cause fulminant
hepatitis. To date, only one other HCV
strain, JFH1 (genotype 1b), has been
isolated that is known to cause
fulminant hepatitis. Additionally, little
is known about the etiology of
fulminant hepatitis C disease. Therefore,
the HC–TN strain may be useful as a
tool for studying the etiology of
fulminant hepatitis. This invention
includes the infectious clone,
nucleotide sequences of the clone, and
polypeptides encoded by the HC–TN
clone. Methods are included for
producing attenuated HCV, and for
screening therapeutics against HCV and
developing vaccines and diagnostics.
Apparently, no companies or other
laboratories have this HC–TN strain.
The availability of the pHC–TN clone
will be highly useful to pharmaceutical
companies since no further research is
required for its commercialization into,
e.g., assays for testing antiviral
compounds targeting HCV.
Applications:
• Production of attenuated viruses
and polypeptides.
• HCV vaccines, diagnostics,
therapeutics and screening tool for antiHCV compounds.
Advantages: There is no universally
effective therapy against HCV infection.
This invention enables development of
vaccines, diagnostics and therapeutics
that are specific for the HC–TN strain or
HCV genotype 1a.
Development Status: The technology
is currently in the preclinical stage of
development.
Market: More than 80% of the HCV
infections in North and South America,
Europe, Russia, China, Japan and
Australia are genotype 1. The instant
technology may be transferred through
biological materials licenses for
territories in which no patent rights
exist.
Inventors: Jens Bukh, Robert H.
Purcell, Suzanne U. Emerson, Akito
Sakai, Patrizia Farci (NIAID).
Publication: A Sakai et al. In vivo
study of the HC–TN strain of hepatitis
C virus recovered from a patient with
fulminant hepatitis: RNA transcripts of
a molecular clone (pHC–TN) are
VerDate Nov<24>2008
16:04 Jul 21, 2009
Jkt 217001
infectious in chimpanzees but not in
Huh7.5 cells. J Virol. 2007
July;81(13):7208–7219.
Patent Status: U.S. Patent Application
No. 12/061,504 filed 02 April 2008
(HHS Reference No. E–249–2007/0–US–
01); No foreign rights available.
Licensing Status: Available for
licensing.
Licensing Contact: RC Tang, JD, LLM;
301–435–5031; tangrc@mail.nih.gov.
Dated: July 13, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Transfer, National
Institutes of Health.
[FR Doc. E9–17319 Filed 7–21–09; 8:45 am]
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: July 14, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–17303 Filed 7–21–09; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Institutes of Health
Healthcare Infection Control Practices
Advisory Committee (HICPAC)
National Institute of Environmental
Health Sciences; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel. Formative Children’s Center
Review 2.
Date: July 24, 2009.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Plaza Hotel, 10 Thomas
Circle, NW., Washington, DC 20005.
Contact Person: Linda K. Bass, PhD,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research and Training, Nat. Institute
Environmental Health Sciences, P. O. Box
12233, MD EC–30, Research Triangle Park,
NC 27709. (919) 541–1307.
malone@niehs.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting for the
aforementioned committee:
Time and Date: 11 a.m.–12 p.m., July 23,
2009.
Place: The teleconference call will
originate at the CDC.
Status: Open to the public. Teleconference
access limited only by availability of
telephone ports. To participate in the
teleconference please dial 1 (800) 779–6036
and enter conference code 6417394.
Purpose: The Committee is charged with
providing advice and guidance to the
Secretary, HHS; the Assistant Secretary for
Health; the Director, CDC; and the Director,
National Center for Preparedness, Detection,
and Control of Infectious Diseases
(NCPDCID), regarding: (1) The practice of
hospital infection control; (2) strategies for
surveillance, prevention, and control of
infections (e.g., nosocomial infections),
antimicrobial resistance, and related events
in settings where healthcare is provided; and
(3) periodic updating of guidelines and other
policy statements regarding prevention of
healthcare-associated infections and
healthcare-related conditions.
Matters To Be Discussed: The agenda will
include a follow up discussion of CDC’s
Interim Guidance for Infection Control for
Care of Patients with Confirmed or Suspected
Novel Influenza A (H1N1) Virus Infection in
a Healthcare Setting.
Agenda items are subject to change as
priorities dictate. This notice is being
published less than 15 days prior to the
meeting due to the public health emergency
declared on April 26, 2009. There is a critical
need for this committee to deliberate and
discuss urgent matters related to the H1N1
virus, and be actively engaged in the national
preparedness and response efforts as dictated
by circumstances and events.
E:\FR\FM\22JYN1.SGM
22JYN1
Federal Register / Vol. 74, No. 139 / Wednesday, July 22, 2009 / Notices
Contact Person For More Information:
Wendy Vance, HICPAC, Division of
Healthcare Quality Promotion, NCPDCID,
CDC, 1600 Clifton Road, NE., Mailstop D–10,
Atlanta, Georgia 30333 Telephone (404) 639–
2891 or HICPAC@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: July 17, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office,Centers for Disease Control and
Prevention (CDC).
[FR Doc. E9–17514 Filed 7–21–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0302]
Withdrawal of Approval of New Animal
Drug Applications; Ketamine; S–
Methoprene; Nitazoxanide
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is withdrawing
approval of two new animal drug
applications (NADAs) and an
abbreviated new animal drug
application (ANADA) listed in table 1 of
this document. In a final rule published
36241
elsewhere in this issue of the Federal
Register, FDA is amending the animal
drug regulations to remove portions
reflecting approval of these NADAs and
ANADA.
DATES: Withdrawal of approval is
effective August 3, 2009.
FOR FURTHER INFORMATION CONTACT: John
Bartkowiak, Center for Veterinary
Medicine (HFV–212), Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240–276–9079, email: john.bartkowiak@fda.hhs.gov.
The
following sponsors have requested that
FDA withdraw approval of the two
NADAs and ANADA listed in table 1 of
this document because the products are
no longer manufactured or marketed:
SUPPLEMENTARY INFORMATION:
TABLE 1.
Sponsor
NADA/ANADA Number
Product (Drug)
21 CFR Cite Affected
(Sponsor Drug Labeler Code)
Wellmark International, 1501 East Woodfield
Rd., suite 200, West Schaumburg, IL 60173
NADA 141–162
Zodiac Fleatrol Flea Caps (S-methoprene)
520.1390 (011536)
NADA 141–178
NAVIGATOR Paste (nitazoxanide)
520.1498 (065274)
ANADA 200–279
KETAFLO Injection (ketamine HCl, USP)
522.1222a (000074)
IDEXX Pharmaceuticals, Inc., 7009 Albert
Pick Rd., Greensboro, NC 27409
Abbott Laboratories, North Chicago, IL 60064
Therefore, under authority delegated
to the Commissioner of Food and Drugs
and redelegated to the Center for
Veterinary Medicine, and in accordance
with § 514.116 Notice of withdrawal of
approval of application (21 CFR
514.116), notice is given that approval
of NADAs 141–162 and 141–178, and
ANADA 200–279, and all supplements
and amendments thereto, are hereby
withdrawn, effective August 3, 2009.
In a final rule published elsewhere in
this issue of the Federal Register, FDA
is amending the animal drug regulations
to reflect the withdrawal of approval of
these NADAs.
Dated: July 14, 2009.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. E9–17408 Filed 7–21–09; 8:45 am]
jlentini on DSKJ8SOYB1PROD with NOTICES
BILLING CODE 4160–01–S
VerDate Nov<24>2008
16:04 Jul 21, 2009
Jkt 217001
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID: FEMA–2009–0001]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
AGENCY: Federal Emergency
Management Agency, DHS.
ACTION: Notice; 60-day notice and
request for comments; revision of a
currently approved information
collection; OMB No. 1660–0095; No
Form.
SUMMARY: The Federal Emergency
Management Agency, as part of its
continuing effort to reduce paperwork
and respondent burden, invites the
general public and other Federal
agencies to take this opportunity to
comment on a proposed revision of a
currently approved information
collection. In accordance with the
Paperwork Reduction Act of 1995, this
Notice seeks comments concerning the
process for the appeal of decisions of
flood insurance claims issued through
the National Flood Insurance Program
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
(NFIP). The appeal process establishes a
formal mechanism to allow
policyholders to appeal the decisions of
any insurance agent, adjuster, insurance
company, or any FEMA employee or
contractor, in cases or unsatisfactory
decisions on claims, proof of loss, and
loss estimates.
DATES: Comments must be submitted on
or before September 21, 2009.
ADDRESSES: To avoid duplicate
submissions to the docket, please use
only one of the following means to
submit comments:
(1) Online. Submit comments at
https://www.regulations.gov under
docket ID FEMA–2009–0001. Follow the
instructions for submitting comments.
(2) Mail. Submit written comments to
Office of Chief Counsel, Regulation and
Policy Team, DHS/FEMA, 500 C Street,
SW., Room 835, Washington, DC 20472–
3100.
(3) Facsimile. Submit comments to
(703) 483–2999.
(4) E-mail. Submit comments to
FEMA-POLICY@dhs.gov. Include docket
ID FEMA–2009–0001 in the subject line.
All submissions received must
include the agency name and docket ID.
Regardless of the method used for
submitting comments or material, all
submissions will be posted, without
E:\FR\FM\22JYN1.SGM
22JYN1
Agencies
[Federal Register Volume 74, Number 139 (Wednesday, July 22, 2009)]
[Notices]
[Pages 36240-36241]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-17514]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Healthcare Infection Control Practices Advisory Committee
(HICPAC)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting for the aforementioned
committee:
Time and Date: 11 a.m.-12 p.m., July 23, 2009.
Place: The teleconference call will originate at the CDC.
Status: Open to the public. Teleconference access limited only
by availability of telephone ports. To participate in the
teleconference please dial 1 (800) 779-6036 and enter conference
code 6417394.
Purpose: The Committee is charged with providing advice and
guidance to the Secretary, HHS; the Assistant Secretary for Health;
the Director, CDC; and the Director, National Center for
Preparedness, Detection, and Control of Infectious Diseases
(NCPDCID), regarding: (1) The practice of hospital infection
control; (2) strategies for surveillance, prevention, and control of
infections (e.g., nosocomial infections), antimicrobial resistance,
and related events in settings where healthcare is provided; and (3)
periodic updating of guidelines and other policy statements
regarding prevention of healthcare-associated infections and
healthcare-related conditions.
Matters To Be Discussed: The agenda will include a follow up
discussion of CDC's Interim Guidance for Infection Control for Care
of Patients with Confirmed or Suspected Novel Influenza A (H1N1)
Virus Infection in a Healthcare Setting.
Agenda items are subject to change as priorities dictate. This
notice is being published less than 15 days prior to the meeting due
to the public health emergency declared on April 26, 2009. There is
a critical need for this committee to deliberate and discuss urgent
matters related to the H1N1 virus, and be actively engaged in the
national preparedness and response efforts as dictated by
circumstances and events.
[[Page 36241]]
Contact Person For More Information: Wendy Vance, HICPAC,
Division of Healthcare Quality Promotion, NCPDCID, CDC, 1600 Clifton
Road, NE., Mailstop D-10, Atlanta, Georgia 30333 Telephone (404)
639-2891 or HICPAC@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: July 17, 2009.
Elaine L. Baker,
Director, Management Analysis and Services Office,Centers for Disease
Control and Prevention (CDC).
[FR Doc. E9-17514 Filed 7-21-09; 8:45 am]
BILLING CODE 4163-18-P